health
They develop an intranasal vaccine against H5N1 avian influenza
A team of scientists from Washington University in St. Louis (United States) has developed an intranasal vaccine against the H5N1 avian influenza virus, capable of generating a robust immune response and preventing infection in animal models.
TL;DR
- A team from Washington University has developed an intranasal vaccine against the H5N1 avian influenza virus.
- The vaccine has shown a robust immune response and prevented infection in animal models.
- Its effectiveness is maintained even in organisms previously immunized or infected with other flu strains.
- The research is significant due to the potential for H5N1 to evolve and cause a human pandemic.
- The vaccine uses nasal vaccine technology previously applied to a COVID-19 vaccine.
- It employs an adenovirus delivery vehicle carrying specific H5N1 proteins.
- Tests in mice and hamsters showed near-complete protection against infection, outperforming seasonal vaccines.
- The nasal spray induced a stronger immune response than intramuscular administration, even at low doses.
- Direct delivery to the upper respiratory tract enhances defense in the nose and lungs, potentially reducing transmission.
- This approach could help curb the spread of H5N1, other flu strains, and respiratory illnesses.
- Further animal and organoid studies are planned to enhance the vaccine's antiviral response.